LA JOLLA, Calif.— Kemp Proteins will take the stage at the 2025 Advanced Lateral Flow Conference (ALFC), where Dr. Carter Mitchell, Chief Scientific Officer, will deliver a featured talk on how machine learning (ML) tools are reshaping recombinant protein development for diagnostics.
Dr. Mitchell’s session, “Designing Better Inputs: How ML Tools Are Reshaping Recombinant Protein Development for Diagnostics,” will be held on Wednesday, October 15, 2025, at the Hilton La Jolla Torrey Pines.
For diagnostics teams racing toward clinical validation or scale-up, protein instability or poor performance can derail entire programs. Yet protein production is often still treated as a “black box.” Dr. Mitchell will discuss how computational tools—from structural modeling to predictive analytics—are changing this. Attendees will learn how bioinformatics, construct design, and process modeling are converging to give developers earlier insight into what will express, what will fold, and what will fail.
Drawing from Kemp Proteins’ work in pandemic preparedness programs and commercial assay development, Dr. Mitchell will share lessons on how smarter protein inputs reduce development risk, improve assay performance, and set the stage for ML-driven optimization pipelines.
“In diagnostics, reproducibility and scalability start with protein design. ML tools are helping us transform what used to be guesswork into a strategic advantage,” said Dr. Mitchell. “We’re excited to show how these approaches are already reshaping antigen development and why they matter for the future of rapid testing.”
Register for ALFC 2025
Join Kemp Proteins and other leaders shaping the future of rapid diagnostics at ALFC 2025, October 14–15 in La Jolla, California. Learn more and register at alfc2025.com.
About Kemp Proteins
Kemp Proteins is a leading provider of protein expression, purification, and characterization services, helping diagnostics, biotech, and pharmaceutical companies accelerate discovery and product development. With expertise spanning recombinant protein production, antibody development, and machine learning-driven workflows, Kemp supports clients in building reliable and scalable biologics programs that enable innovation in healthcare.
To learn more about Kemp proteins, visit kempproteins.com.
About the Advanced Lateral Flow Conference
The Advanced Lateral Flow Conference (ALFC), presented by DCN Dx, is the leading global event for lateral flow diagnostic developers, manufacturers, and those driving their commercial success. This annual conference delivers cutting-edge insights through expert-led sessions and provides a platform for researchers and developers to exchange ideas and innovations. Attendees gain practical insights to advance their businesses, deepen their knowledge of rapid diagnostics, and connect with leading minds shaping the future of point-of-care testing.
The ALFC 2025 theme, Catalyzing Growth: Tech Advancements, Funding, and Regulatory Roadmaps in LFA, focuses on the three pillars driving real-world progress in diagnostics: capital, innovation, and regulatory clarity. From shifting FDA expectations to sustainable funding models and manufacturability challenges, the content will tackle the strategic decisions that shape successful lateral flow products.
Attendees include product managers, business development leads, investors, regulatory professionals, scientists, supply chain reps, and service providers from across the diagnostics ecosystem. These are the people responsible for turning ideas into impact, and ALFC is where they come to learn, connect, and get things done.
To learn more about ALFC, visit alfc2025.com.
About DCN Dx
DCN Dx, based in Carlsbad, California, specializes in lateral flow diagnostics development and manufacturing, and IVD regulatory consulting and clinical research. DCN Dx’s multidisciplinary CDMO specializes in creating tailored assay systems, consumables, and instruments for point-of-use applications, with a particular expertise in lateral flow assays. Their clinical research services group specializes in the planning, execution, and oversight of IVD clinical trials, inclusive of clinical operations, data management, and biostatistics, and regulatory services.
With a commitment to quality, customer satisfaction, and industry-leading expertise, DCN Dx is setting the benchmark for excellence in IVD services. To learn more about how we can support your diagnostic needs, visit dcndx.com.
